Related Experiment Video
Updated: May 7, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Summary
Current Alzheimer's treatments offer limited symptomatic relief for dementia patients. While acetylcholinesterase inhibitors and memantine show modest cognitive benefits, they do not halt disease progression.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Available Alzheimer's disease (AD) and dementia treatments provide limited symptomatic improvement.
- Current pharmacotherapies include acetylcholinesterase inhibitors (AChEIs) and NMDA-receptor antagonists.
Purpose of the Study:
- To review the efficacy and side effect profiles of current AD and dementia pharmacotherapies.
- To assess the current limitations in treating neurodegenerative processes in dementia.
Main Methods:
- Review of clinical trial data for acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine.
- Comparative analysis of efficacy in cognition, daily living, and behavior across disease severities.
- Evaluation of side effect profiles, particularly gastrointestinal effects of rivastigmine formulations.
Main Results:
- AChEIs and memantine demonstrate modest, persistent improvements in cognition, daily living, and behavior.
- Transdermal rivastigmine shows a reduced incidence of gastrointestinal side effects compared to oral forms.
- Combination therapy of memantine with AChEIs shows mixed results regarding enhanced efficacy.
Conclusions:
- Current pharmacotherapies offer symptomatic benefits but do not alter the underlying neurodegenerative pathology of Alzheimer's disease.
- Transdermal rivastigmine presents a favorable side effect profile for managing dementia symptoms.
- Further research is needed to establish the optimal use of combination therapies and disease-modifying treatments.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...